JACC
HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
QUICK SEARCH:   [advanced]


     

J Am Coll Cardiol, 2001; 37:434-439
© 2001 by the American College of Cardiology Foundation
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by von Eckardstein, A.
Right arrow Articles by Assmann, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by von Eckardstein, A.
Right arrow Articles by Assmann, G.

CLINICAL STUDY: ATHEROSCLEROSIS

Lipoprotein(a) further increases the risk of coronary events in men with high global cardiovascular risk

Arnold von Eckardstein, MD*, Helmut Schulte, PhD{dagger}, Paul Cullen, MD, FRCP* and Gerd Assmann, MD, FRCP* {dagger}

* Institut für Klinische Chemie und Laboratoriumsmedizin, Zentrallaboratorium, Westfälische Wilhelms-Universität Münster, Münster, Germany
{dagger} Institut für Arterioskleroseforschung an der Universität Münster, Münster, Germany

Manuscript received June 7, 2000; revised manuscript received August 23, 2000, accepted October 4, 2000.

Reprint requests and correspondence: Dr. Arnold von Eckardstein, Institut für Klinische Chemie und Laboratoriumsmedizin, Zentrallaboratorium, Westfälische Wilhelms-Universität Münster, Albert-Schweitzer-Strasse 33, D-48129 Münster, Germany
vonecka{at}unimuenster.de

OBJECTIVES

This prospective population study was conducted to assess the role of elevated lipoprotein(a) [Lp(a)] as a coronary risk factor.

BACKGROUND

The role of elevated Lp(a) as a risk factor for coronary heart disease is controversial. In addition, little attention has been paid to the interaction of Lp(a) with other risk factors.

METHODS

A total of 788 male participants of the Prospective Cardiovascular Münster (PROCAM) study aged 35 to 65 years were followed for 10 years. Both Lp(a) and traditional cardiovascular risk factors (e.g., age, low density lipoprotein [LDL] cholesterol, high density lipoprotein [HDL] cholesterol, triglycerides, systolic blood pressure, cigarette smoking, diabetes mellitus, angina pectoris, and family history of myocardial infarction) were evaluated in 44 men who suffered from myocardial infarction, and in 744 men who survived without major coronary events or stroke. A multiple logistic function algorithm was used to estimate global cardiovascular risk by the combined effects of traditional risk factors.

RESULTS

Overall, the risk of a coronary event in men with an Lp(a) ≥0.2 g/liter was 2.7 times that of men with lower levels (95% confidence interval [CI]: 1.4 to 5.2). This increase in risk was most prominent in men with LDL cholesterol level ≥4.1 mmol/liter (relative risk [RR]: 2.6; 95% CI: 1.2 to 5.7), with HDL cholesterol ≤0.9 mmol/liter (RR 8.3; 95% CI: 2.0 to 35.5), with hypertension (RR 3.2; 95% CI: 1.4 to 7.2), or within the two highest global risk quintiles (relative risk: 2.7; 95% CI: 1.3 to 5.7).

CONCLUSIONS

Lp(a) increases the coronary risk, especially in men with high LDL cholesterol, low HDL cholesterol, hypertension and/or high global cardiovascular risk.

Abbreviations and Acronyms
  apo = apolipoprotein
  BMI = body mass index
  CHD = coronary heart disease
  HDL = high density lipoprotein
  LDL = low density lipoprotein
  Lp(a) = lipoprotein(a)
  MCE = major coronary event
  MLF = multiple logistic function
  OR = odds ratio
  PROCAM study = Prospective Cardiovascular Münster study




This article has been cited by other articles:


Home page
 J Am Coll CardiolHome page
L. Berglund and E. Anuurad
Role of Lipoprotein(a) in Cardiovascular Disease: Current and Future Perspectives
J. Am. Coll. Cardiol., July 8, 2008; 52(2): 132 - 134.
[Full Text] [PDF]

Home page
 CirculationHome page
P. R. Kamstrup, M. Benn, A. Tybjaerg-Hansen, and B. G. Nordestgaard
Extreme Lipoprotein(a) Levels and Risk of Myocardial Infarction in the General Population: The Copenhagen City Heart Study
Circulation, January 15, 2008; 117(2): 176 - 184.
[Abstract] [Full Text] [PDF]

Home page
 AMERICAN JOURNAL OF LIFESTYLE MEDICINEHome page
J. M. Rippe, T. J. Angelopoulos, and L. Zukley
The Rationale for Intervention to Reduce the Risk of Coronary Heart Disease
American Journal of Lifestyle Medicine, January 1, 2007; 1(1): 10 - 19.
[Abstract] [PDF]

Home page
 CirculationHome page
M. J. Bos, C. M. A. Schipper, P. J. Koudstaal, J. C.M. Witteman, A. Hofman, and M. M.B. Breteler
High Serum C-Reactive Protein Level Is Not an Independent Predictor for Stroke: The Rotterdam Study
Circulation, October 10, 2006; 114(15): 1591 - 1598.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart J SupplHome page
G. Assmann
Dyslipidaemia and global cardiovascular risk: clinical issues
Eur. Heart J. Suppl., October 1, 2006; 8(suppl_F): F40 - F46.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
J. Suk Danik, N. Rifai, J. E. Buring, and P. M Ridker
Lipoprotein(a), measured with an assay independent of apolipoprotein(a) isoform size, and risk of future cardiovascular events among initially healthy women.
JAMA, September 20, 2006; 296(11): 1363 - 1370.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
I. Shai, E. B. Rimm, S. E. Hankinson, C. Cannuscio, G. Curhan, J. E. Manson, N. Rifai, M. J. Stampfer, and J. Ma
Lipoprotein (a) and coronary heart disease among women: beyond a cholesterol carrier?
Eur. Heart J., August 2, 2005; 26(16): 1633 - 1639.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart J SupplHome page
G. Assmann
Calculating global risk: the key to intervention
Eur. Heart J. Suppl., July 1, 2005; 7(suppl_F): F9 - F14.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
C. Hernandez, G. Francisco, P. Chacon, and R. Simo
Lipoprotein(a) as a Risk Factor for Cardiovascular Mortality in Type 2 Diabetic Patients: A 10-year follow-up study
Diabetes Care, April 1, 2005; 28(4): 931 - 933.
[Full Text] [PDF]

Home page
 CirculationHome page
R. Guerra, Z. Yu, S. Marcovina, R. Peshock, J. C. Cohen, and H. H. Hobbs
Lipoprotein(a) and Apolipoprotein(a) Isoforms: No Association With Coronary Artery Calcification in The Dallas Heart Study
Circulation, March 29, 2005; 111(12): 1471 - 1479.
[Abstract] [Full Text] [PDF]

Home page
 British Journal of Diabetes & Vascular DiseaseHome page
E. A Enas, A. Senthilkumar, C. Vinod, and N. Puthumana
Dyslipidaemia among Indo-Asians strategies for identification and management
The British Journal of Diabetes & Vascular Disease, March 1, 2005; 5(2): 81 - 90.
[Abstract] [PDF]

Home page
 Am. J. Clin. Nutr.Home page
K. Hoffmann, B.-C. Zyriax, H. Boeing, and E. Windler
A dietary pattern derived to explain biomarker variation is strongly associated with the risk of coronary artery disease
Am. J. Clinical Nutrition, September 1, 2004; 80(3): 633 - 640.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
N. Rifai, J. Ma, F. M. Sacks, P. M. Ridker, W. J. L. Hernandez, M. J. Stampfer, and S. M. Marcovina
Apolipoprotein(a) Size and Lipoprotein(a) Concentration and Future Risk of Angina Pectoris with Evidence of Severe Coronary Atherosclerosis in Men: The Physicians' Health Study
Clin. Chem., August 1, 2004; 50(8): 1364 - 1371.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
P. M Ridker, N. J. Brown, D. E. Vaughan, D. G. Harrison, and J. L. Mehta
Established and Emerging Plasma Biomarkers in the Prediction of First Atherothrombotic Events
Circulation, June 29, 2004; 109(25_suppl_1): IV-6 - IV-19.
[Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
A. von Eckardstein
Is there a need for novel cardiovascular risk factors?
Nephrol. Dial. Transplant., April 1, 2004; 19(4): 761 - 765.
[Full Text] [PDF]

Home page
 JAMAHome page
A. von Eckardstein
Novel Risk Factors for Atherosclerosis
JAMA, January 21, 2004; 291(3): 301 - 301.
[Full Text] [PDF]

Home page
 JAMAHome page
D. G. Hackam and S. S. Anand
Novel Risk Factors for Atherosclerosis--Reply
JAMA, January 21, 2004; 291(3): 301 - 302.
[Full Text] [PDF]

Home page
 Clin. Chem.Home page
S. M. Marcovina, M. L. Koschinsky, J. J. Albers, and S. Skarlatos
Report of the National Heart, Lung, and Blood Institute Workshop on Lipoprotein(a) and Cardiovascular Disease: Recent Advances and Future Directions
Clin. Chem., November 1, 2003; 49(11): 1785 - 1796.
[Abstract] [Full Text] [PDF]

Home page
 ANGIOLOGYHome page
S. Tsiara, M. Elisaf, and D. P. Mikhailidis
Influence of Smoking on Predictors of Vascular Disease
Angiology, September 1, 2003; 54(5): 507 - 530.
[Abstract] [PDF]

Home page
 ANGIOLOGYHome page
E. S. Ganotakis, K. Mandalaki, M. Tampakaki, N. Malliaraki, E. Mandalakis, G. Vrentzos, J. Melissas, and E. Castanas
Subclinical Hypothyroidism and Lipid Abnormalities in Older Women Attending a Vascular Disease Prevention Clinic: Effect of Thyroid Replacement Therapy
Angiology, September 1, 2003; 54(5): 569 - 576.
[Abstract] [PDF]

Home page
 JAMAHome page
D. G. Hackam and S. S. Anand
Emerging Risk Factors for Atherosclerotic Vascular Disease: A Critical Review of the Evidence
JAMA, August 20, 2003; 290(7): 932 - 940.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
R. A. Kreisberg and A. Oberman
Lipids and Atherosclerosis: Lessons Learned from Randomized Controlled Trials of Lipid Lowering and Other Relevant Studies
J. Clin. Endocrinol. Metab., February 1, 2002; 87(2): 423 - 437.
[Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
A. von Eckardstein, P. Cullen, and G. Assmann
Problems in the measurement of Lp(a) (millimoles per liter versus milligrams percent): Reply
J. Am. Coll. Cardiol., November 1, 2001; 38(5): 1584 - 1585.
[Full Text] [PDF]


HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
Copyright © 2001 by the American College of Cardiology Foundation.